Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413207 | 0.86 | HSD11B1 (0.39) | HSD11B1MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2412918 | 0.86 | HSD11B1 (0.39) | HSD11B1MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2414093 | 0.83 | KMT2A (0.43) | HSD11B1MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2413592 | 0.82 | HSD11B1 (0.41) | HSD11B1MAPTALDH1A1HPGDBCL6 | |
| SCHEMBL2416683 | 0.82 | KMT2A (0.47) | HSD11B1MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2417349 | 0.81 | MAP4K4 (0.38) | HSD11B1AADATSMPD3 | |
| SCHEMBL2416550 | 0.80 | KDM4E (0.30) | ALDH1A1 | |
| SCHEMBL2416453 | 0.80 | HSD11B1 (0.43) | HSD11B1MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2417828 | 0.80 | HSD11B1 (0.41) | HSD11B1MAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2418366 | 0.79 | GAA (0.41) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | claimed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | claimed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | claimed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | claimed |
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | KRT18, DPYD, DSP | HSD11B1 3872/4885MAPT 1318/4885KMT2A 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.